How life sciences companies are measuring their ESG impact

In this episode, Barend van Bergen, EY Global Long-term Value Methodology Leader and Sonja Haut, Head of Impact Valuation for Novartis discuss how companies are measuring their ESG impact.

In this podcast, Barend and Sonja cover a lot of territory. Sonja shares her experience about how companies can make better decisions by embracing non-financial, non-traditional metrics and how the measurement of Impact – to people, planet, and society – has evolved from something ill-defined, to multiple clear frameworks of impact measurement in monetary terms.

Confidence in impact measurement has increased as it has been proven to work, and the argument has moved on from the nitty gritty of excel sheet constructions to the implications of the impact valuation results themselves. Now it’s possible to go beyond stories to underpin work with real data and insight, stakeholder engagement is also easier – ultimately leading to more powerful, far-reaching transformation.

Sonja drills down into the situation in her industry to talk about how companies are having to show the social impact of their medicines, and how this can expand into broader questions of willingness to pay and the trade-offs. On a personal level, she speaks about the Novartis Impact Summit which she has been instrumental in organizing.

The discussion then closes with a look at global use cases, banking for impact and those few gaps in Impact measurement that will have to be addressed in the next five years.

Key takeaways:

  • From not being measured at all, now there are hundreds, possibly thousands, of sustainability metrics.
  • Confidence in sustainability metrics has increased.
  • Sustainability impact data make it increasingly possible to engage stakeholders in potentially transformative conversations.
  • Many innovative sustainable products often need awareness raising around them.
  • Sustainability metrics should help advance business, instead of being “nice-to-have”.

The views of third parties expressed in this podcast are not necessarily the views of the global EY organization or its member firms. Moreover, they should be seen in the context of the time they were made.

For your convenience, full text transcript of this podcast is also available. Read the transcript

Presenters

Barend van Bergen
Partner, Strategy and Transactions, EY-Parthenon B.V.

Podcast

Episode 07

Duration 26m 02s

In this series

Series overview
(Event List - Manual)

How life sciences companies are measuring their ESG impact

In this episode, Barend van Bergen, EY Global Long-term Value Methodology Leader and Sonja Haut, Head of Impact Valuation for Novartis discuss how companies are measuring their ESG impact.
Podcast

Episode 07

Duration
26m 02s

How shorter clinical trial processes prolong the lives of patients

In this episode, Adlai Goldberg asks Tamie Joeckel, ICON’s Cell and Gene Therapy Global Business Lead, if an increased volume of CGT clinical trials with an accelerated process leads to more life-saving approvals.
Podcast

Episode 03

Duration
29m 13s

Presenters

Tamie Joeckel

Cell and Gene Therapy Global Business Lead, ICON

Adlai Goldberg

EY Global Digital, Social and Commercial Innovation Life Sciences Leader

How digital solutions will help close the health equity gap

In this episode, Adlai Goldberg and two prominent chief medical officers explore and frame the health equity challenges the world is facing today.
Podcast

Episode 02

Duration
32m 49s

Presenters

Dr. David Rhew

MD, Chief Medical Officer, Microsoft

Dr. Yele Aluko

MD, US Health Consulting Executive Director, Ernst & Young LLP

The age of ‘Health Experience’

In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of “Health Experience.”
Podcast

Episode 01

Duration
08m 00s

Presenters

Pamela Spence

EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader